Risk of Serious Adverse Drug Events Associated with the Use of Botulinum Toxin Products (Botox)
2007-08-18
The Medicines and Healthcare products Regulatory Agency (MHRA), the British equivalent of the Saudi Food and Drug Authority (SFDA), announced that reports have been received of serious adverse drug reactions, including deaths, associated with the use of botulinum toxin products. Botox is the only brand name product registered by the Ministry of Health in Saudi Arabia.